Sector News

Ex-Sanofi, Schering CEOs were on a short list to replace Valeant chief Pearson: WSJ

March 15, 2016
Life sciences

Plenty of industry-watchers didn’t expect to see embattled Valeant CEO J. Michael Pearson return to the helm after a two-month bout with severe pneumonia. And as it turns out, he almost didn’t.

At one point, the company’s board–which talked with a slate of potential CEO replacements–was leaning toward ousting Pearson, The Wall Street Journal reports. And former Sanofi CEO Chris Viehbacher, interim Valeant CEO Howard Schiller, and former Schering-Plough CEO Fred Hassan, who also had served as chairman of Valeant subsidiary Bausch & Lomb, were on the short list to fill his shoes.

But as high-profile PBMs made moves to freeze out Valeant products, Pearson insisted that his close ties to those companies, as well as insurers and doctors–and his knowledge of what drug discounts the company could afford–made him indispensable, sources told the paper. And the argument worked.

Pearson took back the reins in late February, promising, among other things, to bolster the Canadian drugmaker’s relationships with payers, regulators and government officials. And in his first week on the job, he held drug-pricing talks with reps from Express Scripts, which stopped covering pricey Valeant diabetes med Glumetza once a cheaper generic hit the scene, according to the WSJ. He’s expected to meet with other key Valeant customers in the weeks ahead.

Of course, Pearson’s PBM connections weren’t the only factor working in his favor when it came to re-securing his job. Valeant would have been on the hook for $200 million in deferred stock compensation for him if they’d sent him packing, the Journal notes, and that hefty golden parachute could have sparked investors’ ire.

Since returning, though, Pearson hasn’t taken over all his old responsibilities. The title of chairman now belongs to Robert Ingram, who filled that post while Pearson was out sick. And the company’s board has also kickstarted a search for his successor so it can have a back-up plan, sources told the WSJ.

Meanwhile, Pearson has plenty on his plate aside from the payer negotiations. Congress and politicians still have beef with Valeant over its price-hike strategy, and the SEC is investigating the company’s relationship with former specialty pharmacy Philidor. On top of that, Valeant is behind on its financial reporting, thanks to a Philidor-related earnings restatement and Pearson’s comeback.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.